Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.4 USD | -1.55% | +7.55% | -1.78% |
Apr. 25 | Labcorp beats quarterly estimates on strong testing demand | RE |
Apr. 24 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.78% | 15.28B | A- | ||
-14.73% | 85.42B | B- | ||
+16.05% | 84.38B | C+ | ||
+10.92% | 29.39B | C+ | ||
-12.73% | 17.49B | B | ||
-3.17% | 16.44B | A- | ||
-0.45% | 12.22B | A- | ||
-31.23% | 11.98B | - | - | |
-2.51% | 11.71B | A- | ||
+26.74% | 11.64B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DGX Stock
- Ratings Quest Diagnostics Incorporated